Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cimetidine
Drug ID BADD_D00467
Description A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
Indications and Usage For the treatment and the management of acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion.
Marketing Status Prescription; OTC; Discontinued
ATC Code A02BA01
DrugBank ID DB00501
KEGG ID D00295
MeSH ID D002927
PubChem ID 2756
TTD Drug ID D02DPA
NDC Product Code 63029-222; 0378-0317; 0093-8192; 0378-0372; 42291-218; 49452-2063; 62991-1456; 70934-931; 30142-323; 71052-456; 63629-1783; 53002-3280; 0093-8204; 0395-8079; 42291-217; 49035-820; 50090-3574; 70518-2809; 0363-0022; 0093-8305; 0378-0541; 38779-0325; 55289-581; 49964-0006; 51552-0531; 59779-022; 69256-022; 49711-0095; 51927-2750; 63629-1497; 63187-333; 49348-246; 0378-0053; 50090-0500; 72288-022; 24385-111; 51927-0190; 0113-0022
Synonyms Cimetidine | N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine | Biomet | Biomet400 | Cimetidine Hydrochloride | Hydrochloride, Cimetidine | Cimetidine HCl | HCl, Cimetidine | Histodil | SK&F-92334 | SK&F 92334 | SK&F92334 | SKF-92334 | SKF 92334 | SKF92334 | Tagamet | Altramet | Eureceptor
Chemical Information
Molecular Formula C10H16N6S
CAS Registry Number 51481-61-9
SMILES CC1=C(N=CN1)CSCCNC(=NC)NC#N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Haemolytic anaemiaUDP-glucuronosyltransferase 1A1P22309T934809059066; 9695674; 9746775; 1683484; 1981005; 9127818; 11967601; 9390057
Haemolytic anaemiaL-lactate dehydrogenase B chainP07195Not Available9059066; 9695674; 9746775; 1683484; 1981005; 9127818; 11967601; 9390057
Hyperparathyroidism secondaryParathyroid hormoneP01270T987086689302; 6547988; 6090499
Hyperparathyroidism secondaryCalcineurin subunit B type 1P63098Not Available6689302; 6547988; 6090499
ThrombocytopeniaBifunctional epoxide hydrolase 2P34913T357348326296; 3966212; 3614578; 9101005
ThrombocytopeniaL-lactate dehydrogenase C chainP07864Not Available9059066; 9695674; 9746775; 1683484; 1981005; 9127818; 11967601; 9390057
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Drug hypersensitivity10.01.01.0010.011462%Not Available
Drug withdrawal syndrome19.07.02.011; 08.06.02.0040.022924%Not Available
Dyspnoea22.02.01.004; 02.01.03.0020.005731%
Electrocardiogram QT prolonged13.14.05.0040.014328%
Erythema23.03.06.0010.005731%Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Flatulence07.01.04.002--
Food interaction08.06.03.0020.017193%Not Available
Galactorrhoea21.05.02.002; 05.03.04.002--Not Available
Gastric perforation12.02.03.007; 07.04.03.0010.008597%
Gynaecomastia21.05.04.003; 05.05.02.003--
Haemolytic anaemia01.06.03.002--Not Available
Hallucination19.10.02.002--
Headache17.14.01.001--
Hepatic failure09.01.03.002--
Hepatic fibrosis24.08.06.002; 09.01.04.002--Not Available
Hepatitis09.01.07.004--Not Available
Hepatotoxicity12.03.01.008; 09.01.07.009--Not Available
Hypersensitivity10.01.03.003--
Hypersensitivity vasculitis24.05.02.012; 23.06.02.005; 10.02.02.017; 01.01.04.008--Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.008597%Not Available
Leukopenia01.02.02.001--Not Available
Malaise08.01.01.0030.005731%
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Mydriasis17.02.11.003; 06.05.03.0040.008597%Not Available
Nausea07.01.07.001--
Neutropenia01.02.03.004--Not Available
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages